There is: No evidence that Epitalon can shrink existing tumors in humans No human clinical trials testing its use in oncology No mechanistic studies confirming how Epitalon affects tumor microenvironments or immune evasion in vivo What we do have is a compelling preventive profile in animal models, especially where aging and genetic susceptibility intersect
It has become a foundational component of many cellular optimization protocols
A dedicated phase 2a substudy in people with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) used MRI to measure liver fat and found that, after 24 weeks, retatrutide reduced relative liver-fat content by about 81% at the 8 mg dose and about 82% at 12 mg, versus essentially no change on placebo
939 A15 Medicare Current Beneficiary Survey Report: These data come from an analysis of findings from the 2018 Medicare Current Beneficiary Survey (MCBS)
Key Benefits with BPC-157: Improves sleep and recovery during REM cycles Increases IGF-1 for ligament and cartilage regeneration Enhances muscle tissue repair and lean mass retention Boosts collagen synthesis, supporting long-term joint resilience Ideal for stacking when recovering from repetitive strain injuries, joint degradation, or tendonitis , where deeper structural repair is needed
Bidirectional Communication Bidirectional communication manifests in multiple experimental paradigms: From brain to gut: Selye-type stress leading to gastroduodenal ulcers was counteracted by BPC-157, which modulated hypothalamic-pituitary-adrenal (HPA) axis function and vagal signaling
